<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138941</url>
  </required_header>
  <id_info>
    <org_study_id>APLC LLDAS Study</org_study_id>
    <nct_id>NCT03138941</nct_id>
  </id_info>
  <brief_title>Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region</brief_title>
  <acronym>APLCLLDAS</acronym>
  <official_title>Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Flinders Medical Centre, Adelaide, AUSTRALIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Vincent's Hospital, Melbourne, AUSTRALIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Adelaide Hospital, Adelaide, AUSTRALIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New South Wales, Sydney, AUSTRALIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital, Peking University Health Science Center, Beijing, CHINA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital, Beijing, CHINA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Hong Kong, HONG KONG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padjadjaran, Bandung, INDONESIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo Women's Medical University, JAPAN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Occupational and Environmental Health, JAPAN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keio University, JAPAN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University Hospital for Rheumatic Diseases, REPUBLIC OF KOREA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Santo Tomas Hospital, Philippines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital, TAIWAN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiang Mai University Hospital, THAILAND</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dubai Hospital, Dubai, UNITED ARAB EMIRATES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Middlemore Hospital, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Shore Hospital, Auckland, NEW ZEALAND</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective
      study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the
      attainment of LLDAS is associated with improved outcomes in patients with Systemic Lupus
      Erythematosus (SLE).

      SLE, or lupus, is the archetypal multisystem autoimmune disease, with an estimated incidence
      of 5-50 cases per 100,000 people. Patients with SLE, usually young women, suffer a marked
      loss of life expectancy, and severe morbidity, due to a heterogeneous range of clinical
      manifestations caused by autoimmune-mediated inflammation of multiple organs. The most severe
      manifestations of SLE are the accrual of irreversible organ damage, especially renal and
      central nervous system (CNS) involvement. As there is no effective targeted monotherapy for
      SLE, patients also suffer severe toxicity from the use of glucocorticoids and broad-spectrum
      immunosuppressive therapies. Despite combination therapy with current drugs, many studies
      show that the majority of patients suffer inadequate disease control and inexorably accrue
      permanent organ damage over time.

      The diversity of clinical features of active SLE has made quantification of disease activity
      problematic. Although there are a number of published systems in use to measure SLE disease
      activity, there are widely acknowledged problems with these instruments. Published
      definitions of remission are so stringent that they are met by less than 5% of patients. This
      lead to the realisation that rather than lupus remission, a lupus low disease activity state
      target may be more feasible, and that patients with low disease activity are more homogeneous
      than patients with active disease. Thus, the development of a definition of lupus low disease
      activity, which is feasible and has face validity, escapes the complexity of attempts to
      quantify heterogeneous states of active disease.

      In this study, the investigators will prospectively collect longitudinal data on consecutive
      SLE patients at each centre to evaluate the LLDAS definition. Protection from organ damage
      accrual as the primary endpoint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients with SLE will be followed for ~ 5 years. Regular recordings of the
      data needed to score LLDAS (disease activity and treatment domains, see Franklyn L et al, Ann
      Rheum Dis 2016) will be collected, as well as annual recording of lupus-related damage using
      the SLICC_ACR Damage Index (SDI) and quality of life using the Short Form 36 version 2
      (SF36v2).

      At conclusion of primary data collection, the associate of LLDAS attainment, or sustained
      attainment, with protection from organ damage accrual will be ascertained.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>SLICC-ACR Damage Index</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Organ damage accrual</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SFv2-36</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult SLE patients with confirmed lupus
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients have to meet either the 1997 American College of Rheumatology (ACR)
             Modified Classification Criteria for SLE, with at least four of the 11 items; or
             alternatively, fulfil the Systemic Lupus International Collaborating Clinics (SLICC)
             2012 Classification Criteria, with at least four of the 17 items (at least one
             clinical and one immunological criterion) or with lupus nephritis in the presence of
             at least one immunological criteria. Patients can be either newly diagnosed or
             longstanding lupus patients.

        All patients must be over the age of 18 and competent to provide written consent.

        Exclusion Criteria:

          -  Patients less than 18 years of age and patients who are unable to consent are excluded
             from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Morand</last_name>
    <role>Study Chair</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric F Morand</last_name>
    <phone>+ 61 3 8572 2650</phone>
    <email>eric.morand@monash.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rangi K KANDANE-RATHNAYAKE</last_name>
    <phone>+ 61 3 8572 2561</phone>
    <email>Rangi.Kandane-Rathnayake@monash.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean O'Neill</last_name>
      <email>Sean.O'Neill@sswahs.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Goldblatt</last_name>
      <email>Fiona.Goldblatt@health.sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Goldblatt</last_name>
      <email>Fiona.Goldblatt@health.sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing &amp; Health Sciences</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Morand</last_name>
      <email>eric.morand@monash.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alberta Hoi</last_name>
      <email>alberta.hoi@monash.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vera Golder</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, St Vincent's Hospital (Melbourne)</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandana Nikpour</last_name>
      <email>m.nikpour@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology and Immunology, People's Hospital Peking University Health Science Center</name>
      <address>
        <city>Beijing</city>
        <state>Western District</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhan Guo Li</last_name>
      <email>li99@bjmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yuan An</last_name>
      <email>anyfield@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Immunology department, Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Xicheng district</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuoli Zhang</last_name>
      <email>zhuoli.zhang@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanjie Hao</last_name>
      <email>hyjbb@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology &amp; Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong</name>
      <address>
        <city>Pok Fu Lam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Padjadjaran University/ Hasan Sadikin General Hospital</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laniyati Hamijoyo</last_name>
      <email>hamijoyo@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health</name>
      <address>
        <city>Japan</city>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiya Tanaka</last_name>
      <email>tanaka@med.uoeh-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Kazuhisa Nakano</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ippei Miyagawa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsutomu Takeuchi</last_name>
      <email>tsutake@z5.keio.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology, Tokyo Women's Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>162-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masayoshi Harigai</last_name>
      <email>mharigai.mpha@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yasuhiro Katsumata</last_name>
      <email>katsumata@ior.twmu.ac.jp</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Cheol Bae</last_name>
      <email>scbae@hanyang.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Faculty of Medicine Building, University of Malaya</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joint and Bone Center, University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1008</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Navarra</last_name>
      <email>sandra_navarra@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatology Division, University Medical Cluster, National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aisha Lateef</last_name>
      <email>Aisha_LATEEF@nuhs.edu.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Allergy &amp; Immunology, Tan Tock Seng Hospital</name>
      <address>
        <city>Tan Tock Seng</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madelynn Chan</last_name>
      <email>madelynn_chan@ttsh.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Allergy and Immunology Chang Gung Memorial Hospital Chang Gung University</name>
      <address>
        <city>Guishan</city>
        <state>Taoyuan County</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shue Fen Luo</last_name>
      <email>lsf00076@adm.cgmh.org.tw</email>
    </contact>
    <contact_backup>
      <last_name>Yeong-Jian Wu</last_name>
      <email>yjwu1962@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Hsing Chen</last_name>
      <email>dr.yihsing@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <state>Muang District</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Worawit Louthrenoo</last_name>
      <email>wlouthre@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Dubai Hospital</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamal Al-Saleh</last_name>
      <email>jaalsaleh@dha.gov.ae</email>
    </contact>
    <contact_backup>
      <last_name>Munther Khamashta</last_name>
      <email>munther.khamashta@kcl.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Indonesia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>http://www.asiapacificlupus.com/</url>
  </link>
  <reference>
    <citation>Golder V, Huq M, Franklyn K, Calderone A, Lateef A, Lau CS, Lee ALH, Navarra STV, Godfrey T, Oon S, Hoi AYB, Morand EF, Nikpour M. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. Semin Arthritis Rheum. 2017 Jun;46(6):798-803. doi: 10.1016/j.semarthrit.2017.01.007. Epub 2017 Jan 18.</citation>
    <PMID>28216192</PMID>
  </reference>
  <reference>
    <citation>Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017 Mar 20;19(1):62. doi: 10.1186/s13075-017-1256-6.</citation>
    <PMID>28320433</PMID>
  </reference>
  <reference>
    <citation>Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Lee AL, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Morand EF, Nikpour M; Asia-Pacific Lupus Collaboration. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther. 2016 Nov 9;18(1):260.</citation>
    <PMID>27829463</PMID>
  </reference>
  <reference>
    <citation>Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726. Epub 2015 Oct 12.</citation>
    <PMID>26458737</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monash University</investigator_affiliation>
    <investigator_full_name>Eric F Morand</investigator_full_name>
    <investigator_title>Professor of Medicine; Head, School of Clinical Sciences at Monash Health, Monash University;DIrector, Rheumatology, Monash Health</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Patient data collected and collated by the Asia Pacific Lupus Collaboration (APLC) is guided by strict protocols and procedures to ensure that privacy and other ethical principles are maintained at all times. Data sharing will strictly follows the APLC Data Access Policy. Under no circumstances will individual subject data be made available to any third parties.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

